Atibuclimab

Modify Date: 2025-08-28 01:40:50

Atibuclimab structure	Common Name	Atibuclimab
	CAS Number	2417175-94-9	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Atibuclimab

Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis[1]. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist[2].

Name	Atibuclimab

Description	Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis[1]. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist[2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
References	[1]. Henderson RD, Agosti JM, McCombe PA, et al. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine (Baltimore). 2021;100(42):e27421. [2]. Verbon A, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol. 2001;166(5):3599-3605.

Description

Related Catalog

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

References

[1]. Henderson RD, Agosti JM, McCombe PA, et al. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine (Baltimore). 2021;100(42):e27421.

[2]. Verbon A, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol. 2001;166(5):3599-3605.

No Any Chemical & Physical Properties